Evidence map›Paper›PMID 29550996›Full record

ArticleParasitology research2018

Molecular docking to Toxoplasma gondii thymidylate synthase-dihydrofolate reductase and efficacy of raltitrexed in infected mice.

Michelle de Paula Reis, Daniely Alves de Lima, Karoline Bach Pauli, Carlos Eduardo Linhares Andreotti, André Luiz Soares de Moraes, Daniela Dib Gonçalves, Italmar Teodorico Navarro, Paulo Sérgio Alves Bueno, Flavio Augusto Vicente Seixas, Arquimedes Gasparotto Junior and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Parasitology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Evaluation ofMetabolites · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Michelle de Paula ReisLaboratory of Preclinical Research of Natural Products, Universidade Paranaense, Umuarama, PR, Brazil.
Daniely Alves de LimaLaboratory of Preclinical Research of Natural Products, Universidade Paranaense, Umuarama, PR, Brazil.
Karoline Bach PauliLaboratory of Preclinical Research of Natural Products, Universidade Paranaense, Umuarama, PR, Brazil.
Carlos Eduardo Linhares AndreottiLaboratory of Preclinical Research of Natural Products, Universidade Paranaense, Umuarama, PR, Brazil.
André Luiz Soares de MoraesLaboratory of Preclinical Research of Natural Products, Universidade Paranaense, Umuarama, PR, Brazil.
Daniela Dib GonçalvesLaboratory of Preclinical Research of Natural Products, Universidade Paranaense, Umuarama, PR, Brazil.
Italmar Teodorico NavarroAnimal Science Department, Londrina State University, Londrina, PR, Brazil.
Paulo Sérgio Alves BuenoLaboratory of Structural Biochemistry, Universidade Estadual de Maringá, Maringá, PR, Brazil.
Flavio Augusto Vicente SeixasLaboratory of Structural Biochemistry, Universidade Estadual de Maringá, Maringá, PR, Brazil.
Arquimedes Gasparotto JuniorLaboratory of Electrophysiology and Cardiovascular Pharmacology, Faculty of Health Sciences, Universidade Federal da Grande Dourados, Rodovia Dourados-Itahum, km 12, P.O. Box 533, 79, Dourados, MS, 804-970, Brazil. arquimedesjunior@ufgd.edu.br.ORCID http://orcid.org/0000-0003-3433-5098
Emerson Luiz Botelho LourençoLaboratory of Preclinical Research of Natural Products, Universidade Paranaense, Umuarama, PR, Brazil.
Universidade Paranaense · BRUniversidade Estadual de Maringá · BRUniversidade Estadual de Londrina · BRUniversidade Federal da Grande Dourados · BR

Funding

Fundação Araucária 147/14
6 · The paper itself

Abstract

Toxoplasmosis is a zoonosis of worldwide distribution. Currently, two drugs, pyrimethamine and sulfadiazine, are used as a reference in the treatment of toxoplasmosis, but the resistance of Toxoplasma gondii appears as a relevant public health problem. In order to identify new drugs to toxoplasmosis treatment, we performed a molecular docking of raltitrexed to T. gondii thymidylate synthase-dihydrofolate reductase (TS-DHFR) and also evaluated its efficacy in infected mice. Initially, raltitrexed was docked on the crystallographic structures of TS-DHFR from T. gondii and Mus musculus. Then, 48 h after infection with the T. gondii RH strain, different groups of mice received an oral dose of raltitrexed (0.15, 0.75, and 1.5 mg kg

Indexed as

AnimalsAntimetabolites, AntineoplasticHumansMaleMiceMolecular Docking SimulationMultienzyme ComplexesQuinazolinesTetrahydrofolate DehydrogenaseThiophenesThymidylate SynthaseToxoplasmaToxoplasmosis, AnimalAntimetabolites, AntineoplasticMultienzyme ComplexesQuinazolinesraltitrexedTetrahydrofolate DehydrogenaseThiophenesThymidylate Synthasethymidylate synthase-dihydrofolate reductaseChemotherapyInfectionProtozoanRH strainTachyzoites

Identifiers

PMID29550996
OpenAlexW2791705190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.